LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan Labs Ltd	CIMDUO	lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	022141	NDA	Viatris Specialty LLC	49502-450-93	1 BOTTLE, PLASTIC in 1 CARTON (49502-450-93) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC	2018-06-25
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 12, 2025

Introduction

Lamivudine and Tenofovir Disoproxil Fumarate (TDF) are cornerstone antiretroviral agents widely used in the management of HIV/AIDS. Their global demand stems from their proven efficacy, safety profiles, and integration into combination therapies. The supply landscape for these drugs involves a complex ecosystem of innovator companies, generic manufacturers, and contract manufacturing organizations (CMOs), each operating within regulated markets to ensure quality and compliance.

Understanding key suppliers for Lamivudine and TDF is critical for stakeholders—including pharmaceutical companies, healthcare providers, policymakers, and investors—seeking secure, reliable access to these essential medicines. This analysis explores the landscape of suppliers, the geographical distribution, and factors shaping the availability of these drugs.

Market Overview of Lamivudine and Tenofovir Disoproxil Fumarate

Lamivudine (brand name Epivir) and Tenofovir Disoproxil Fumarate (brand names Viread, Vemlidy) are nucleoside reverse transcriptase inhibitors (NRTIs). Their role in first-line antiretroviral therapy (ART) regimens is well-established, often combined with other agents such as Dolutegravir or Emtricitabine.

The global supply chain is characterized by:

Established multinational pharmaceutical companies holding patents
A significant number of generic manufacturing entities, especially in countries like India and China
Increasing efforts to produce affordable, quality-assured generics to support global HIV programs, particularly in low- and middle-income countries (LMICs)

Major Suppliers for Lamivudine

1. Originator Companies

Gilead Sciences: The original developer of Lamivudine (Epivir), historically supplied branded medication globally. Gilead's patents provided exclusivity but have since expired in many jurisdictions, facilitating generic proliferation.
GlaxoSmithKline (GSK): Previously owned the patent rights in certain markets.

2. Leading Generic Manufacturers

Hetero Labs Ltd. (India): A prominent producer of Lamivudine, with WHO prequalification. Hetero supplies to numerous international procurement agencies.
Mylan (now part of Viatris): Global supplier with a significant footprint in low-cost, high-volume generics.
Cipla: A major Indian pharmaceutical company with WHO prequalified products.
Ferozson Laboratories (Pakistan): Supplies generics primarily within Asia and to international agencies.
Lupin Ltd.: Indian manufacturer with WHO prequalification.

3. Regional and Emerging Suppliers

Several Chinese companies, such as Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., are emerging suppliers.
Other Indian firms such as Strides Pharma and Hetero are increasing their market presence.

Key Suppliers for Tenofovir Disoproxil Fumarate

1. Originator Companies

Gilead Sciences: Developed TDF, with widespread patent rights historically held globally.
Fudao Pharmaceutical: Partnered in some markets for manufacturing.

2. Primary Generics Manufacturers

Hetero Labs Ltd.: Among the first to produce WHO-prequalified TDF, playing a vital role in global health programs.
Cipla: Also produces WHO-prequalified TDF, widely used in LMICs.
Mylan (Viatris): Offers affordable TDF formulations, including fixed-dose combinations.
Lupin Ltd.: Another Indian manufacturer with significant capacity.
Aurobindo Pharma: Active in producing TDF for international markets.
Shenzhen Salubris Pharmaceutical Co., Ltd.: Chinese supplier increasing presence.

3. Contract Manufacturing & Licensing

Gilead has used licensing agreements with Indian companies to increase access, especially following patent expirations.
Such partnerships allow multiple suppliers to produce TDF under licensing agreements, expanding the supply chain.

Regulatory and Market Dynamics Influencing Suppliers

Patent Expiries: The expiration of Gilead’s patents in many countries (e.g., India in 2013) led to a surge in generic manufacturing.
WHO Prequalification: Critical for supplying international donor-funded programs (e.g., PEPFAR, Global Fund). Most WHO-prequalified Lamivudine and TDF products originate from Indian and Chinese manufacturers.
Trade Agreements and Patent Laws: Variations across jurisdictions influence which companies can produce and market these drugs.
Cost Competition: Indian generics dominate as low-cost suppliers due to manufacturing efficiency and less stringent patent enforcement.

Emerging Suppliers and Future Trends

Bioproduction & Biosimilars: No direct biosimilar equivalents for Lamivudine or TDF currently exist; however, innovation is ongoing.
Innovative Formulations: Suppliers are exploring long-acting formulations and fixed-dose combinations to improve adherence.
Global Access Initiatives: Suppliers aligned with global procurement agencies will remain pivotal for meeting access goals.

Supply Chain Risks and Considerations

Regulatory Delays: Certification and prequalification delays can impact availability.
Quality Assurance: Increased scrutiny ensures that new suppliers meet international standards.
Geopolitical Factors: Trade tensions and export restrictions may disrupt supply flows.
Manufacturing Capacity: Scaling up production necessitates significant investment; bottlenecks can lead to shortages.

Conclusion

The global supply of Lamivudine and Tenofovir Disoproxil Fumarate is predominantly driven by Indian generic manufacturers, with established players such as Hetero, Cipla, Mylan, and Lupin significantly contributing to the market. These entities provide quality-assured, low-cost medicines essential for global HIV/AIDS programs. Patent expiries and licensing agreements continue to diversify and expand the supplier base, enhancing access and affordability.

Stakeholders must monitor supply chain developments, regulatory approvals, and geopolitical dynamics to ensure sustained access and mitigate risks. The increasing presence of Chinese manufacturers is also shaping future supply avenues, while efforts to develop innovative formulations signal ongoing evolution in the access landscape.

Key Takeaways

Indian generic companies are the primary suppliers of Lamivudine and TDF, providing affordable, WHO-prequalified options.
Gilead remains a key innovator brand but relies on licensing agreements and generic partnerships for broader market penetration.
Regulatory approvals, particularly WHO prequalification, are essential for participation in global health programs.
Patent expirations have significantly expanded the supplier ecosystem, encouraging competition and reducing prices.
Continued diversification of suppliers and manufacturing capacity is vital to prevent shortages and ensure global demand is met.

FAQs

1. Who are the top suppliers of Lamivudine globally?
Indian pharmaceutical companies such as Hetero Labs, Cipla, Mylan (Viatris), and Lupin dominate the global supply of Lamivudine, especially for use in LMICs.

2. Are there patent restrictions affecting the supply of Tenofovir Disoproxil Fumarate?
Yes, patent protections by Gilead historically limited generic production. However, patent expiries in key markets, including India, have enabled multiple generics to enter the market.

3. How does WHO prequalification influence supplier selection?
WHO prequalification certifies that generic manufacturers meet international quality standards, making their products eligible for procurement by global health agencies.

4. What are the risks to the supply of these drugs?
Risks include regulatory delays, patent disputes, manufacturing disruptions, geopolitical tensions, and quality control issues.

5. Will the supplier landscape for these drugs change in the future?
Yes. Emerging manufacturers in China and other countries, along with ongoing innovation and licensing arrangements, are expected to diversify and expand the supply base further.

References

[1] World Health Organization. List of prequalified medicinal products.
[2] Gilead Sciences. HIV and Hepatitis Drug Portfolio.
[3] Indian Pharmaceutical Alliance. Market Analysis Reports.
[4] Global Fund Procurement Policies.
[5] Patent Expiry Notices, Indian Patent Office.

Suppliers and packagers for generic pharmaceutical drug: LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE